Renaissance Technologies’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Renaissance Technologies’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,226	Closed	-$6K	–	4706
2022 Q1	$6K	Sell	1,226 -8,133	-87%	-$51.1K	﹤0.01%	4032
2021 Q4	$53K	Buy	+9,359	New	+$79.6K	﹤0.01%	3781
2021 Q3	–	Sell	-100,526	Closed	-$1.7M	–	4003
2021 Q2	$1.7M	Buy	+100,526	New	+$1.91M	﹤0.01%	2367
2020 Q3	–	Sell	-18,574	Closed	-$788K	–	3807
2020 Q2	$788K	Buy	18,574 +17,627	+1,861%	+$1.19M	﹤0.01%	2667
2020 Q1	$76K	Sell	947 -2,210	-70%	-$177K	﹤0.01%	3273
2019 Q4	$292K	Buy	3,157 +2,124	+206%	+$179K	﹤0.01%	3079
2019 Q3	$78K	Buy	+1,033	New	+$79.3K	﹤0.01%	3291
2017 Q3	–	Sell	-623	Closed	-$30K	–	3439
2017 Q2	$30K	Buy	623 +504	+424%	+$88.3K	﹤0.01%	3148
2017 Q1	$17K	Buy	+119	New	+$15.4K	﹤0.01%	3180

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies's EVFM Position: Q2 2022 in Review

Renaissance Technologies sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,226 shares — an estimated $6K sold.

Renaissance Technologies first reported a position in EVFM in Q1 2017 and held it in 9 quarters. The position peaked at $1.7M in Q2 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Renaissance Technologies reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Renaissance Technologies sold 1,226 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $6K.
Renaissance Technologies first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2017 and held it in 9 quarters.
Renaissance Technologies's Evofem Biosciences, Inc. Common Stock position peaked at $1.7M in Q2 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.